Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Immatics N.V.

Immatics ( ($IMTX) ) just unveiled an announcement. Immatics N.V., a Nasdaq-listed biotech company headquartered in Houston and Tübingen, focuses o...

Immatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer Programs

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AEON Biopharma (AEON), BioMarin Pharmaceutical (BM...

Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON), BioMarin Pharmaceutical (BMRN) and Immatics (IMTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN), Immatics (IMTX) and ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMTX	$9.45	+0.96%	1.09M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMTX	$9.45	+1.0%	1.09M
3
4
5
6

IMTX

Get Immatics N.V. Data in Excel

Get Immatics N.V. Data in Excel